in 2000, and also its drug formulation technology for $575 million (LIPO shareholders getting about $15.28 per share).Now Elan is selling Abelcet for $370 million in cash. 575-370=$205 million for the rest of Liposome.LIPO had more drugs in their pipeline (including liposomal doxorubicin: Myocet). Anybody know what happen to the rest of the Liposome pipeline?
LIPO shareholder got ELN stock which at the time worth 25 times more than today's. Based today's valuation, ELN was paying only 20 some million of LIPO. What a steal for ELN and it is the LIPO sharehold that got screwed.